Inhibiting Endothelin Receptors withMacitentan Strengthens the Bone Protective Action of RANKL Inhib...
Inhibiting Endothelin Receptors withMacitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
About this item
Full title
Author / Creator
Publisher
MDPI
Journal title
Language
English
Formats
Publication information
Publisher
MDPI
Subjects
More information
Scope and Contents
Contents
Current treatments for osteosarcoma, combining conventional polychemotherapy and surgery, make it possible to attain a five-year survival rate of 70% in affected individuals. The presence of chemoresistance and metastases significantly shorten the patient’s lifespan, making identification of new therapeutic tools essential. Inhibiting bone resorpti...
Alternative Titles
Full title
Inhibiting Endothelin Receptors withMacitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_inserm_03625367v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_inserm_03625367v1
Other Identifiers
ISSN
2072-6694
E-ISSN
2072-6694
DOI
10.3390/cancers14071765
